Dementia and Alzheimer Disease

The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]

ACU193 treatment reduced amyloid plaques in early Alzheimer disease patients, suggesting AßOs as a viable target, with safety data and ARIA analysis presented at CTAD 2023.

The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.

Patients with mild Alzheimer disease who received high doses of BIIB080 demonstrated improvement in cognitive and functional outcomes compared with placebo, supporting further investigation.

The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

New subcutaneous lecanemab considered more effective than IV for amyloid plaque removal in Alzheimer disease; FDA application planned by March 2024.

The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]

Findings from the phase 2a AscenD-LB, a study of neflamapimod in patients with mild-to-moderate Alzheimer disease, served as supportive data to guide the phase 2b study.

Findings from the trial demonstrated rapid and sustained clinical response in patients with Alzhiemer disease agitation during the open-label treatment phase and did not show any new safety signals.

The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]

Over the 18-month treatment period, investigators observed no amyloid-related imaging abnormalities along with continued slowing of disease progression in patients with mild to moderate Alzheimer disease.

Diego Torres-Russotto, MD, chair of neurology at Baptist Health Miami Neuroscience Institute, provided an overview of the upcoming 11th Annual Miami Neuroscience Symposium, a 3-day educational event held in early November.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is rare and genetic neurological disorders.

Among football players, odds of having a parkinsonism or Parkinson disease diagnosis were greater with more seasons and higher level of football play.

Neurology News Network for the week ending October 21, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 20, 2023.

In a recent clinical trial, patients who received SaiLuoTong showed improvements in aspects of memory and executive function including delayed episodic memory retrieval, switching between cognitive concepts, higher-level divided attention, and multitasking compared with placebo.

Solanezumab did not slow the progression of preclinical Alzheimer disease as compared with placebo on the basis of the primary or secondary cognitive and functional end points over a 4.5-year treatment period.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the European Committe for Treatment and Research in Multiple Sclerosis.

Neurology News Network for the week ending October 14, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 13, 2023.

The decision opens the door for greater access to PET imaging that can assist in timely diagnosis of Alzheimer disease and facilitate with appropriate treatment decisions.

The professor of ophthalmology and neurology at Duke University School of Medicine talked about a recent published study on using artificial intelligence and retinal scans to detect mild cognitive impairment in neurodegenerative diseases including Alzheimer disease. [WATCH TIME: 7 minutes]